secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001104659-23-002024
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood cuts FY2022 revenue guidance to ~$411M; issues FY2023 outlook and files sNDA for pediatric LINZESS
--------------------------------------------------------------------------------

- Updated FY2022: total revenue ~$411M (prev. $420-430M), LINZESS net sales ~0% growth, adj. EBITDA ~$250M.
- FY2023 guidance: revenue $420-435M, LINZESS net sales growth 3-5%, adj. EBITDA >$250M.
- sNDA submitted to FDA for LINZESS in functional constipation in children 6-17; if approved, first FDA therapy for this population.
- Expects ~$650M cash at YE2022; high single-digit LINZESS prescription demand growth in 2023.
- Clinical milestone: CNP-104 data expected in H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465923002024/0001104659-23-002024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465923002024/tm232274d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-002024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer